Rani Therapeutics RANI 深 滬
等待開盤 06-25 09:30:00 美东时间
0.767
+0.012
+1.59%
華盛通- 最 高0.79
- 今 開0.7885
- 成交量 74.46万股
- 最 低 0.7502
- 昨 收 0.755
- 總市值 1.05亿
- 52周最高 3.87
- 市盈率 靜 --
- 換手率 0.55%
- 52周最低 0.387
- 委 比 -89.47%
- 總股本 1.36亿
- 歷史最高 36.27
- 量 比 1.41
- 振 幅 5.27%
- 歷史最低 0.387
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GLP-1/GLP-2双激动剂，治疗肥胖：拿到新一轮融资
注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。 药融...
06-04 17:12
Rani Therapeutics stockholders elect directors at annual meeting
Rani Therapeutics stockholders elect directors at annual meeting Rani Therapeutics held its annual shareholder meeting on May 28, 2026. Shareholders backed the selection of the company’s director nominees to serve until the 2027 annual meeting. Shareholders ratified CBIZ CPAs P.C. as independent reg
05-29 18:04
Rani Therapeutics shares are trading lower after the company priced a $20 million registered direct offering.
Rani Therapeutics shares are trading lower after the company priced a $20 milli...
05-27 00:43
Rani Therapeutics Prices ~$20M Offering Of 12.48M Common Shares At $1.07/Share
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a
05-26 20:04
Rani Therapeutics CFO Sanford to depart
Rani Therapeutics (RANI) said on Friday that chief financial officer Svai Sanford will leave the company after a successor is appointed, as the company announced a series of leadership changes and ope...
05-16 05:00
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice
The latest update is out from Rani Therapeutics Holdings ( ($RANI) ). Rani Ther...
05-16 04:34
Rani Therapeutics Hldgs Q1 EPS $(0.04), Inline, Sales $1.708M Beat $500.000K Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 81.82 percent increase over losses of $(0.22) per share from the same period last
05-16 04:07
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
Rani Therapeutics reported Q1 2026 financial results and updates, including the advancement of its Phase 1 RT-114 obesity trial via RaniPill® in collaboration with ProGen, and key leadership changes: Alireza Javadi, Ph.D. as CTO, Jesper Høiland as Head of Strategy, and Dr. Sara Kenkare-Mitra as Strategic Advisor. The company also announced the transition of Chief Financial Officer Svai Sanford, who will remain during the transition period. Financ...
05-15 20:05
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
Rani Therapeutics announced that its management team will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026. CEO Talat Imran and CFO Svai Sanford will engage in a Fireside Chat and 1x1 meetings. The event will be webcast live from the company's website, with a replay available post-presentation. Rani Therapeutics specializes in oral delivery of biologics and drugs, utilizing its proprietary Ran...
05-12 20:05
New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market
PatentVest's report highlights the rapid expansion of triple-agonist programs in obesity therapeutics, with 27 global projects across major pharma companies and emerging biotechs. The study emphasizes the shift from clinical outcomes to intellectual property strategies, receptor engineering, and delivery systems as key factors shaping the next phase of competition. China is a significant player in this pipeline expansion. Companies like Eli Lilly...
05-08 14:30
